IMV News and Press, IMV Inc. From 08/13/19

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

IMV, Inc. (IMV) Q2 2019 Earnings Conference Call August 09, 2019, 08:00 ET Company Participants Pierre Labbé - CFO Frederic Ors - President, CEO & Director Gabriela Rosu - Chief Medical Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & C...

IMV (NASDAQ: IMV ): Q2 GAAP EPS of -C$0.10 beats by C$0.03 . More news on: IMV Inc., Earnings news and commentary, , Read more ...

Presented updated data from Phase 2 monotherapy arm of DeCidE1 study at ASCO 2019; DPX-Survivac exhibited durable clinical benefit with progression-free survival in patients with advanced recurrent ovarian cancer Reported positive new data from Phase 2 SPiReL combination study of D...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that company management will be presenting at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019 at 3:30 p.m. ET in Boston, MA. A live webcast of the presentation wil...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, August 9, 2019 at 8:00 a.m. ET to discuss the company’s second quarter 2019 fina...

Updated results from a Phase 2 clinical trial, SPiReL , evaluating IMV's (NASDAQ: IMV ) lead candidate DPX-Survivac, combined with low-dose cyclophosphamide and Merck's (NYSE: MRK ) Keytruda (pembrolizumab), in patients with persistent or relapsed/refractory diffuse large B-cell lymphoma...

Complete radiologic responses linked to T cell activity observed in two of first six evaluable patients IMV to host investor conference call and webcast on June 12, 2019 at 8:00 am ET IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced up...